Humanized immunoglobulin reacting specifically with fas ligand or active fragments thereof and region inducing apoptosis originating in fas ligand
CA 2264968 A1 · Owner: Nakata, Motomi · Inventors: Ushio, Yoshitaka; Okumura, Ko; Maeda, Hiroaki
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A novel humanized immunoglobulin reacting specifically with a Fas ligand and active fragments thereof are provided and a region on a Fas ligand which is important in inhibiting apoptosis induced by cells with Fas expression on the basis of the Fas-Fas ligand interaction is clarified. The novel humanized immunoglobulin and active fragments thereof are prepared by the recombinant DNA techniques from hybridomas which produce a monoclonal antibody reacting specifically with a Fas ligand. This immunoglobulin can inhibit physiological reactions between a Fas ligand and Fas typified by apoptosis. By specifying , the region participating in the induction of apoptosis on a Fas ligand there , …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 27, 1997. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended August 27, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 27, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.